Oncology News

Women with gynecologic cancer and COVID-19 demonstrated a high risk for hospitalization, cancer treatment delays and death, according to a study presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.

The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

A trained artificial intelligence model predicted treatment outcomes before surgery of women with high-grade serous ovarian cancer, according to study results.

Data published in Cell Reports Medicine showed that endometriosis was genetically linked to ovarian cancer.

Nearly one-third of older women who survived colorectal, endometrial or ovarian cancer reported lower extremity lymphedema, according to data published in JAMA Network Open.

Breast arterial calcification seen on a routine mammogram may independently predict atherosclerotic CVD and global CVD risk for postmenopausal women, according to research published in Circulation: Cardiovascular Imaging.

About one-third of women with commercial insurance underwent genetic testing for ovarian cancer between 2008 and 2018 despite unequivocal recommendations for universal testing, according to research in JAMA Network Open.

Three of six women with metastatic breast cancer who received investigational tumor-infiltrating lymphocytes plus pembrolizumab demonstrated tumor reductions greater than 50%, according to phase 2 study results.

An estimated 1 in 7 screen-detected breast cancers in biennially screened women aged 50 to 74 years will be overdiagnosed, according to an analysis of an authoritative U.S. population data set published in Annals of Internal Medicine.

Premenopausal women with a first-degree family history of breast cancer had greater mammographic breast density than those without a family history of breast cancer, according to a study in JAMA Network Open.